Eikon Therapeutics, Inc. (EIKN)
$6.72-7.44%Close
SELL
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $20M
- Beta
- 0.94
- P/E (TTM)
- -1.45
- Short % float
- 214.14%
- Days to cover
- 8.8
- SI change
- +15.4%
- 1W
- -10.52%
- 1M
- -28.21%
- vs SPY 1W
- -10.38%
- vs SPY 1M
- -30.71%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 19
- VALUE
- 17
- GROWTH
- 41
- GARP
- 8
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC116.1%
REV YoY-
ROE193.4%
EPS YoY-
ROA-41.3%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-1.45
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.78
P/FCF-
EV/EBITDA-1.59
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E54.07
ALTMAN Z-
CURR RATIO9.89
ND/EBITDA-
BETA0.94
Company news
FAQ
- What is LOPJLB’s current signal on EIKN?
- LOPJLB’s latest quantitative signal on Eikon Therapeutics, Inc. Common Stock (EIKN) is SELL. Signals are updated daily.
- What market regime is EIKN in?
- LOPJLB classifies each ticker into BULL, RECOVERY, BEAR, or CRISIS regimes using a Hidden Markov Model.
- What does Eikon Therapeutics, Inc. Common Stock (EIKN) do?
- Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's dru…